Back

Lentiviral vector optimization enhances the expression and cytotoxicity of chimeric antigen receptors

Guo, C.; Chen, H.; Yu, J.; Lu, H.; Guo, X.; Li, X.; Wang, T.; Zhi, L.; Niu, Z.; Zhu, W.

2021-07-12 cell biology
10.1101/2021.07.11.451925 bioRxiv
Show abstract

Adoptive chimeric antigen receptor (CAR)-modified T or NK cells (CAR-T/NK) have emerged as a novel form of disease treatment. Lentiviral vectors (LVs) are commonly employed to engineer T/NK cells for the efficient expression of CARs. This study reported for the first time the influence of single-promoter and dual-promoter LVs on the CAR expression and cytotoxicity of engineered NK cells. Our results demonstrated that the selected CAR exhibits both a higher expression level and a higher coexpression concordance with the GFP reporter in HEK-293T or NK92 cells by utilizing the optimized single-promoter pCDHsp rather than the original dual-promoter pCDHdp. After puromycin selection, the pCDHsp produces robust CAR expression and enhanced in vitro cytotoxicity of engineered NK cells. Therefore, infection with a single-promoter pCDHsp lentivector is recommended to prepare CAR-engineered cells. This research will help to optimize the production of CAR-NK cells and improve their functional activity, to provide CAR-NK cell products with better and more uniform quality.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
Cell Discovery
○ 57 papers in training set
Top 0.1%
7.3%
2
Acta Biochimica et Biophysica Sinica
● 23 papers in training set
Top 0.1%
6.3%
3
eLife
● 5828 papers in training set
Top 18%
6.3%
4
Journal of Molecular Cell Biology
◐ 22 papers in training set
Top 0.1%
5.5%
5
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.2%
5.2%
6
Cell Structure and Function
● 11 papers in training set
Top 0.1%
4.9%
7
Protein & Cell
◐ 25 papers in training set
Top 0.1%
3.4%
8
Scientific Reports
○ 3612 papers in training set
Top 33%
3.3%
9
Biochemical and Biophysical Research Communications
○ 84 papers in training set
Top 0.6%
2.4%
10
PLOS ONE
● 5266 papers in training set
Top 42%
2.4%
11
Molecular Therapy
○ 81 papers in training set
Top 0.8%
1.9%
12
iScience
○ 1154 papers in training set
Top 16%
1.7%
50% of probability mass above
13
Cell & Bioscience
○ 14 papers in training set
Top 0.1%
1.7%
14
International Immunopharmacology
○ 15 papers in training set
Top 0.1%
1.5%
15
Annals of Translational Medicine
○ 18 papers in training set
Top 0.3%
1.5%
16
Cancer Medicine
○ 26 papers in training set
Top 0.6%
1.5%
17
Advanced Science
○ 286 papers in training set
Top 5%
1.5%
18
Genes to Cells
○ 25 papers in training set
Top 0.3%
1.3%
19
Life
○ 29 papers in training set
Top 0.5%
1.1%
20
Clinical and Translational Medicine
○ 31 papers in training set
Top 0.5%
1.1%
21
Frontiers in Immunology
○ 638 papers in training set
Top 7%
1.1%
22
Stem Cell Research & Therapy
○ 30 papers in training set
Top 0.5%
1.1%
23
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 1%
1.1%
24
Theranostics
● 37 papers in training set
Top 0.8%
1.0%
25
International Journal of Biological Macromolecules
○ 76 papers in training set
Top 2%
1.0%
26
The FASEB Journal
○ 194 papers in training set
Top 4%
1.0%
27
Science China Life Sciences
○ 29 papers in training set
Top 0.5%
0.9%
28
Cancer Letters
○ 35 papers in training set
Top 1%
0.9%
29
Cell Death Discovery
○ 58 papers in training set
Top 1%
0.9%
30
Nature Communications
○ 5641 papers in training set
Top 56%
0.9%